nodes	percent_of_prediction	percent_of_DWPC	metapath
Bromocriptine—type 2 diabetes mellitus—polycystic ovary syndrome	0.523	1	CtDrD
Bromocriptine—ADRA1D—polycystic ovary syndrome	0.151	0.412	CbGaD
Bromocriptine—ADRA1B—polycystic ovary syndrome	0.129	0.352	CbGaD
Bromocriptine—ADRA1A—polycystic ovary syndrome	0.0865	0.237	CbGaD
Bromocriptine—Taste metallic—Metformin—polycystic ovary syndrome	0.00202	0.119	CcSEcCtD
Bromocriptine—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.000794	0.0468	CcSEcCtD
Bromocriptine—CYP1A2—urine—polycystic ovary syndrome	0.000652	0.0703	CbGeAlD
Bromocriptine—Ergonovine—ADRA1A—polycystic ovary syndrome	0.000608	0.296	CrCbGaD
Bromocriptine—Ergotamine—ADRA1D—polycystic ovary syndrome	0.000596	0.29	CrCbGaD
Bromocriptine—Lightheadedness—Metformin—polycystic ovary syndrome	0.000575	0.0339	CcSEcCtD
Bromocriptine—Nasal congestion—Metformin—polycystic ovary syndrome	0.000512	0.0302	CcSEcCtD
Bromocriptine—HTR2A—urine—polycystic ovary syndrome	0.00051	0.0549	CbGeAlD
Bromocriptine—Ergotamine—ADRA1B—polycystic ovary syndrome	0.000509	0.247	CrCbGaD
Bromocriptine—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.000478	0.0282	CcSEcCtD
Bromocriptine—Lethargy—Metformin—polycystic ovary syndrome	0.000476	0.0281	CcSEcCtD
Bromocriptine—CYP3A4—urine—polycystic ovary syndrome	0.000472	0.0509	CbGeAlD
Bromocriptine—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000426	0.0251	CcSEcCtD
Bromocriptine—Cramp muscle—Metformin—polycystic ovary syndrome	0.00042	0.0248	CcSEcCtD
Bromocriptine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000417	0.0246	CcSEcCtD
Bromocriptine—Influenza—Metformin—polycystic ovary syndrome	0.000403	0.0238	CcSEcCtD
Bromocriptine—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000387	0.0228	CcSEcCtD
Bromocriptine—Drowsiness—Metformin—polycystic ovary syndrome	0.00036	0.0212	CcSEcCtD
Bromocriptine—Ergotamine—ADRA1A—polycystic ovary syndrome	0.000342	0.167	CrCbGaD
Bromocriptine—Bradycardia—Metformin—polycystic ovary syndrome	0.000329	0.0194	CcSEcCtD
Bromocriptine—Rhinitis—Metformin—polycystic ovary syndrome	0.000324	0.0191	CcSEcCtD
Bromocriptine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000321	0.0189	CcSEcCtD
Bromocriptine—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000318	0.0188	CcSEcCtD
Bromocriptine—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000317	0.0187	CcSEcCtD
Bromocriptine—DRD5—female gonad—polycystic ovary syndrome	0.000305	0.0329	CbGeAlD
Bromocriptine—Eye disorder—Metformin—polycystic ovary syndrome	0.000302	0.0178	CcSEcCtD
Bromocriptine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.0003	0.0177	CcSEcCtD
Bromocriptine—Angiopathy—Metformin—polycystic ovary syndrome	0.000293	0.0173	CcSEcCtD
Bromocriptine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000291	0.0172	CcSEcCtD
Bromocriptine—DRD5—endocrine gland—polycystic ovary syndrome	0.000284	0.0306	CbGeAlD
Bromocriptine—Dysgeusia—Metformin—polycystic ovary syndrome	0.000275	0.0162	CcSEcCtD
Bromocriptine—Muscle spasms—Metformin—polycystic ovary syndrome	0.00027	0.0159	CcSEcCtD
Bromocriptine—Vision blurred—Metformin—polycystic ovary syndrome	0.000265	0.0156	CcSEcCtD
Bromocriptine—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000253	0.0273	CbGeAlD
Bromocriptine—Syncope—Metformin—polycystic ovary syndrome	0.000252	0.0149	CcSEcCtD
Bromocriptine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000247	0.0146	CcSEcCtD
Bromocriptine—Hypertension—Metformin—polycystic ovary syndrome	0.000243	0.0143	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000238	0.014	CcSEcCtD
Bromocriptine—Oedema—Metformin—polycystic ovary syndrome	0.000229	0.0135	CcSEcCtD
Bromocriptine—Infection—Metformin—polycystic ovary syndrome	0.000228	0.0134	CcSEcCtD
Bromocriptine—ADRA1D—endocrine gland—polycystic ovary syndrome	0.000228	0.0245	CbGeAlD
Bromocriptine—HTR2B—endometrium—polycystic ovary syndrome	0.000226	0.0243	CbGeAlD
Bromocriptine—Shock—Metformin—polycystic ovary syndrome	0.000226	0.0133	CcSEcCtD
Bromocriptine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000225	0.0133	CcSEcCtD
Bromocriptine—Skin disorder—Metformin—polycystic ovary syndrome	0.000223	0.0131	CcSEcCtD
Bromocriptine—Anorexia—Metformin—polycystic ovary syndrome	0.000219	0.0129	CcSEcCtD
Bromocriptine—Hypotension—Metformin—polycystic ovary syndrome	0.000214	0.0126	CcSEcCtD
Bromocriptine—ADRB1—adipose tissue—polycystic ovary syndrome	0.000213	0.0229	CbGeAlD
Bromocriptine—HTR2B—uterus—polycystic ovary syndrome	0.000208	0.0224	CbGeAlD
Bromocriptine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000206	0.0121	CcSEcCtD
Bromocriptine—Dyspnoea—Metformin—polycystic ovary syndrome	0.000205	0.0121	CcSEcCtD
Bromocriptine—Somnolence—Metformin—polycystic ovary syndrome	0.000204	0.012	CcSEcCtD
Bromocriptine—HTR2B—adipose tissue—polycystic ovary syndrome	0.000203	0.0219	CbGeAlD
Bromocriptine—Dyspepsia—Metformin—polycystic ovary syndrome	0.000202	0.0119	CcSEcCtD
Bromocriptine—Decreased appetite—Metformin—polycystic ovary syndrome	0.000199	0.0118	CcSEcCtD
Bromocriptine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000199	0.0215	CbGeAlD
Bromocriptine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000198	0.0117	CcSEcCtD
Bromocriptine—Fatigue—Metformin—polycystic ovary syndrome	0.000198	0.0117	CcSEcCtD
Bromocriptine—Constipation—Metformin—polycystic ovary syndrome	0.000196	0.0116	CcSEcCtD
Bromocriptine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000189	0.0111	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000188	0.0111	CcSEcCtD
Bromocriptine—HTR2B—adrenal gland—polycystic ovary syndrome	0.000183	0.0197	CbGeAlD
Bromocriptine—Urticaria—Metformin—polycystic ovary syndrome	0.000182	0.0107	CcSEcCtD
Bromocriptine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000181	0.0107	CcSEcCtD
Bromocriptine—ADRA2C—endometrium—polycystic ovary syndrome	0.000178	0.0192	CbGeAlD
Bromocriptine—HTR1B—endocrine gland—polycystic ovary syndrome	0.000176	0.0189	CbGeAlD
Bromocriptine—HTR2B—vagina—polycystic ovary syndrome	0.000169	0.0182	CbGeAlD
Bromocriptine—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000168	0.0181	CbGeAlD
Bromocriptine—DRD2—pituitary gland—polycystic ovary syndrome	0.000165	0.0178	CbGeAlD
Bromocriptine—ADRB1—endocrine gland—polycystic ovary syndrome	0.000165	0.0178	CbGeAlD
Bromocriptine—HTR2A—embryo—polycystic ovary syndrome	0.000165	0.0178	CbGeAlD
Bromocriptine—Asthenia—Metformin—polycystic ovary syndrome	0.000165	0.00971	CcSEcCtD
Bromocriptine—ADRA2C—uterus—polycystic ovary syndrome	0.000164	0.0177	CbGeAlD
Bromocriptine—HTR1A—adrenal gland—polycystic ovary syndrome	0.000164	0.0176	CbGeAlD
Bromocriptine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000161	0.0173	CbGeAlD
Bromocriptine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.00016	0.0173	CbGeAlD
Bromocriptine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000157	0.00926	CcSEcCtD
Bromocriptine—HTR7—adrenal gland—polycystic ovary syndrome	0.000156	0.0169	CbGeAlD
Bromocriptine—Dizziness—Metformin—polycystic ovary syndrome	0.000152	0.00895	CcSEcCtD
Bromocriptine—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000151	0.0163	CbGeAlD
Bromocriptine—Vomiting—Metformin—polycystic ovary syndrome	0.000146	0.0086	CcSEcCtD
Bromocriptine—Rash—Metformin—polycystic ovary syndrome	0.000145	0.00853	CcSEcCtD
Bromocriptine—Dermatitis—Metformin—polycystic ovary syndrome	0.000145	0.00852	CcSEcCtD
Bromocriptine—Headache—Metformin—polycystic ovary syndrome	0.000144	0.00848	CcSEcCtD
Bromocriptine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000144	0.0155	CbGeAlD
Bromocriptine—HTR1A—endocrine gland—polycystic ovary syndrome	0.000142	0.0153	CbGeAlD
Bromocriptine—ADRA2A—endometrium—polycystic ovary syndrome	0.000142	0.0153	CbGeAlD
Bromocriptine—Nausea—Metformin—polycystic ovary syndrome	0.000136	0.00804	CcSEcCtD
Bromocriptine—HTR7—endocrine gland—polycystic ovary syndrome	0.000136	0.0146	CbGeAlD
Bromocriptine—ADRA2C—female gonad—polycystic ovary syndrome	0.000134	0.0144	CbGeAlD
Bromocriptine—ADRA2C—vagina—polycystic ovary syndrome	0.000133	0.0144	CbGeAlD
Bromocriptine—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000131	0.0141	CbGeAlD
Bromocriptine—ADRA2A—uterus—polycystic ovary syndrome	0.000131	0.0141	CbGeAlD
Bromocriptine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000128	0.0138	CbGeAlD
Bromocriptine—DRD2—endocrine gland—polycystic ovary syndrome	0.000128	0.0138	CbGeAlD
Bromocriptine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000128	0.0138	CbGeAlD
Bromocriptine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000115	0.0124	CbGeAlD
Bromocriptine—HTR2A—pituitary gland—polycystic ovary syndrome	0.000109	0.0118	CbGeAlD
Bromocriptine—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000108	0.0117	CbGeAlD
Bromocriptine—ABCB1—embryo—polycystic ovary syndrome	0.000108	0.0116	CbGeAlD
Bromocriptine—ADRA2A—female gonad—polycystic ovary syndrome	0.000107	0.0115	CbGeAlD
Bromocriptine—ADRA2A—vagina—polycystic ovary syndrome	0.000106	0.0115	CbGeAlD
Bromocriptine—ADRA2A—endocrine gland—polycystic ovary syndrome	9.94e-05	0.0107	CbGeAlD
Bromocriptine—HTR2A—adrenal gland—polycystic ovary syndrome	9.75e-05	0.0105	CbGeAlD
Bromocriptine—HTR2A—vagina—polycystic ovary syndrome	9.03e-05	0.00974	CbGeAlD
Bromocriptine—ABCB1—adrenal cortex—polycystic ovary syndrome	8.85e-05	0.00954	CbGeAlD
Bromocriptine—HTR2A—endocrine gland—polycystic ovary syndrome	8.45e-05	0.00911	CbGeAlD
Bromocriptine—ABCB1—endometrium—polycystic ovary syndrome	7.9e-05	0.00852	CbGeAlD
Bromocriptine—CYP3A4—endocrine gland—polycystic ovary syndrome	7.82e-05	0.00844	CbGeAlD
Bromocriptine—ABCB1—uterus—polycystic ovary syndrome	7.28e-05	0.00785	CbGeAlD
Bromocriptine—ABCB1—pituitary gland—polycystic ovary syndrome	7.15e-05	0.00771	CbGeAlD
Bromocriptine—ABCB1—adipose tissue—polycystic ovary syndrome	7.12e-05	0.00768	CbGeAlD
Bromocriptine—ABCB1—adrenal gland—polycystic ovary syndrome	6.39e-05	0.00689	CbGeAlD
Bromocriptine—ABCB1—female gonad—polycystic ovary syndrome	5.96e-05	0.00642	CbGeAlD
Bromocriptine—ABCB1—vagina—polycystic ovary syndrome	5.92e-05	0.00638	CbGeAlD
Bromocriptine—ABCB1—endocrine gland—polycystic ovary syndrome	5.54e-05	0.00597	CbGeAlD
Bromocriptine—HTR6—Signaling Pathways—AKT2—polycystic ovary syndrome	1.93e-06	2.3e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—IGF1—polycystic ovary syndrome	1.93e-06	2.3e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—AKT2—polycystic ovary syndrome	1.92e-06	2.3e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—POMC—polycystic ovary syndrome	1.92e-06	2.29e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	1.91e-06	2.29e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	1.91e-06	2.29e-05	CbGpPWpGaD
Bromocriptine—DRD5—Signaling by GPCR—IL6—polycystic ovary syndrome	1.91e-06	2.28e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.91e-06	2.28e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—INS—polycystic ovary syndrome	1.91e-06	2.28e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	1.9e-06	2.28e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.9e-06	2.28e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.9e-06	2.27e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.9e-06	2.27e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.87e-06	2.24e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.87e-06	2.24e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	1.87e-06	2.24e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.87e-06	2.23e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.86e-06	2.23e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.84e-06	2.21e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	1.84e-06	2.21e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.84e-06	2.2e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	1.84e-06	2.2e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	1.83e-06	2.2e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.83e-06	2.19e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.83e-06	2.19e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.83e-06	2.19e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.83e-06	2.19e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	1.82e-06	2.18e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.82e-06	2.17e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.81e-06	2.17e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.81e-06	2.16e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.81e-06	2.16e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.79e-06	2.14e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.79e-06	2.14e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.78e-06	2.13e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.78e-06	2.13e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.78e-06	2.12e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—IRS1—polycystic ovary syndrome	1.77e-06	2.11e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.77e-06	2.11e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.76e-06	2.11e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	1.76e-06	2.11e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.76e-06	2.11e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.76e-06	2.1e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.76e-06	2.1e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—TH—polycystic ovary syndrome	1.75e-06	2.1e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.75e-06	2.1e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.75e-06	2.09e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	1.74e-06	2.09e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.74e-06	2.08e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.74e-06	2.08e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	1.74e-06	2.08e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	1.74e-06	2.08e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.73e-06	2.07e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.73e-06	2.07e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.73e-06	2.07e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	1.72e-06	2.06e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.72e-06	2.06e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	1.72e-06	2.05e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	1.72e-06	2.05e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.71e-06	2.04e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	1.71e-06	2.04e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	1.71e-06	2.04e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—POMC—polycystic ovary syndrome	1.7e-06	2.04e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	1.7e-06	2.04e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.7e-06	2.04e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—INS—polycystic ovary syndrome	1.69e-06	2.03e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	1.69e-06	2.03e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.68e-06	2.01e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.67e-06	2e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.67e-06	2e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.66e-06	1.99e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.66e-06	1.98e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.65e-06	1.97e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.65e-06	1.97e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	1.64e-06	1.97e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	1.64e-06	1.97e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—IGF1—polycystic ovary syndrome	1.64e-06	1.96e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.64e-06	1.96e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—AKT2—polycystic ovary syndrome	1.64e-06	1.96e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.64e-06	1.96e-05	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.63e-06	1.95e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.62e-06	1.94e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	1.62e-06	1.94e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.61e-06	1.93e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	1.6e-06	1.92e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.6e-06	1.91e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.58e-06	1.89e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.55e-06	1.86e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.55e-06	1.86e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.55e-06	1.86e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.55e-06	1.85e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	1.54e-06	1.85e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.54e-06	1.84e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.54e-06	1.84e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.53e-06	1.83e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	1.53e-06	1.83e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.52e-06	1.82e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.52e-06	1.81e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	1.52e-06	1.81e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.49e-06	1.79e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	1.49e-06	1.78e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.49e-06	1.78e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.49e-06	1.78e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.49e-06	1.78e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.48e-06	1.77e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.48e-06	1.77e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.48e-06	1.77e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.48e-06	1.77e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	1.48e-06	1.76e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	1.47e-06	1.76e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—IL6—polycystic ovary syndrome	1.47e-06	1.76e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.47e-06	1.76e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	1.47e-06	1.76e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.47e-06	1.76e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	1.46e-06	1.75e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.46e-06	1.75e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.44e-06	1.72e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.43e-06	1.71e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	1.43e-06	1.71e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	1.43e-06	1.71e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.43e-06	1.71e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.43e-06	1.71e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	1.42e-06	1.7e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	1.42e-06	1.7e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.42e-06	1.69e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.42e-06	1.69e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	1.41e-06	1.69e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	1.41e-06	1.69e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	1.41e-06	1.69e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	1.4e-06	1.68e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.4e-06	1.68e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	1.4e-06	1.68e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	1.39e-06	1.67e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.39e-06	1.66e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	1.39e-06	1.66e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	1.38e-06	1.65e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	1.38e-06	1.65e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	1.36e-06	1.63e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	1.36e-06	1.63e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.36e-06	1.63e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.36e-06	1.63e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.36e-06	1.62e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	1.36e-06	1.62e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.35e-06	1.62e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.35e-06	1.62e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.35e-06	1.61e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.35e-06	1.61e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.34e-06	1.61e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.33e-06	1.59e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.31e-06	1.57e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.3e-06	1.56e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	1.3e-06	1.56e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	1.3e-06	1.55e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.29e-06	1.55e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.29e-06	1.54e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	1.28e-06	1.53e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	1.28e-06	1.53e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	1.27e-06	1.52e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.27e-06	1.52e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.27e-06	1.52e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.26e-06	1.51e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.26e-06	1.5e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.25e-06	1.5e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.25e-06	1.5e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.25e-06	1.5e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—IL6—polycystic ovary syndrome	1.25e-06	1.5e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.25e-06	1.5e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.25e-06	1.49e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.25e-06	1.49e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	1.25e-06	1.49e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.23e-06	1.47e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.23e-06	1.47e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.22e-06	1.46e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.21e-06	1.45e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.21e-06	1.44e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.21e-06	1.44e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.21e-06	1.44e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.2e-06	1.44e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.19e-06	1.42e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.17e-06	1.4e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	1.17e-06	1.39e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	1.16e-06	1.39e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.15e-06	1.38e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.15e-06	1.37e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	1.14e-06	1.37e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.14e-06	1.36e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.13e-06	1.35e-05	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	1.13e-06	1.35e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.12e-06	1.34e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.12e-06	1.34e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.09e-06	1.31e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.09e-06	1.3e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.09e-06	1.3e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.08e-06	1.3e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.08e-06	1.29e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.07e-06	1.28e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.07e-06	1.28e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.06e-06	1.27e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.06e-06	1.26e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.05e-06	1.26e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.04e-06	1.24e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.03e-06	1.24e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	9.88e-07	1.18e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	9.78e-07	1.17e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.74e-07	1.17e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.65e-07	1.16e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—POMC—polycystic ovary syndrome	9.64e-07	1.15e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	9.62e-07	1.15e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—INS—polycystic ovary syndrome	9.59e-07	1.15e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	9.58e-07	1.15e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	9.43e-07	1.13e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.32e-07	1.12e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.27e-07	1.11e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	9.23e-07	1.1e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.02e-07	1.08e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.88e-07	1.06e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	8.82e-07	1.06e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	8.71e-07	1.04e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—IL6—polycystic ovary syndrome	8.7e-07	1.04e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	8.64e-07	1.03e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	8.58e-07	1.03e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	8.46e-07	1.01e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	8.4e-07	1.01e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	8.33e-07	9.96e-06	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.18e-07	9.79e-06	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.05e-07	9.63e-06	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	7.97e-07	9.53e-06	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	7.95e-07	9.51e-06	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.88e-07	9.43e-06	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	7.8e-07	9.34e-06	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	7.7e-07	9.21e-06	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	7.65e-07	9.16e-06	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	7.5e-07	8.97e-06	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	7.43e-07	8.89e-06	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—IL6—polycystic ovary syndrome	7.4e-07	8.85e-06	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	7.4e-07	8.85e-06	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.32e-07	8.76e-06	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	6.74e-07	8.06e-06	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	6.68e-07	7.99e-06	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	6.45e-07	7.71e-06	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	6.41e-07	7.67e-06	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	6.24e-07	7.46e-06	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	6.14e-07	7.34e-06	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	6.02e-07	7.21e-06	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	5.94e-07	7.11e-06	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—INS—polycystic ovary syndrome	5.91e-07	7.07e-06	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	5.66e-07	6.77e-06	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	5.57e-07	6.66e-06	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	5.45e-07	6.52e-06	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	5.07e-07	6.06e-06	CbGpPWpGaD
